-$0.41 Earnings Per Share Expected for Proteon Therapeutics, Inc. (PRTO) This Quarter

Wall Street brokerages predict that Proteon Therapeutics, Inc. (NASDAQ:PRTO) will report earnings per share (EPS) of ($0.41) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Proteon Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.48) and the highest estimate coming in at ($0.34). Proteon Therapeutics posted earnings of ($0.42) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 2.4%. The company is scheduled to report its next earnings report on Thursday, March 15th.

On average, analysts expect that Proteon Therapeutics will report full year earnings of ($1.79) per share for the current fiscal year, with EPS estimates ranging from ($2.30) to ($1.42). For the next financial year, analysts anticipate that the business will post earnings of ($1.64) per share, with EPS estimates ranging from ($1.81) to ($1.35). Zacks’ earnings per share calculations are a mean average based on a survey of research analysts that follow Proteon Therapeutics.

A number of analysts recently weighed in on the company. Zacks Investment Research upgraded Proteon Therapeutics from a “hold” rating to a “strong-buy” rating and set a $2.50 price objective for the company in a report on Tuesday, October 17th. HC Wainwright reiterated a “hold” rating and set a $2.30 price target on shares of Proteon Therapeutics in a report on Wednesday. Robert W. Baird reiterated a “hold” rating and set a $2.00 price target on shares of Proteon Therapeutics in a report on Friday. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Proteon Therapeutics in a report on Wednesday, August 16th. Finally, Cowen and Company reiterated a “hold” rating on shares of Proteon Therapeutics in a report on Tuesday, August 8th. One analyst has rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the stock. The company has an average rating of “Hold” and an average target price of $6.13.

An institutional investor recently bought a new position in Proteon Therapeutics stock. RA Capital Management LLC purchased a new position in shares of Proteon Therapeutics, Inc. (NASDAQ:PRTO) in the second quarter, according to its most recent filing with the SEC. The firm purchased 1,337,462 shares of the biopharmaceutical company’s stock, valued at approximately $2,040,000. Proteon Therapeutics accounts for 0.2% of RA Capital Management LLC’s portfolio, making the stock its 22nd largest holding. RA Capital Management LLC owned 7.59% of Proteon Therapeutics as of its most recent SEC filing. 47.07% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “-$0.41 Earnings Per Share Expected for Proteon Therapeutics, Inc. (PRTO) This Quarter” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2017/11/12/0-41-earnings-per-share-expected-for-proteon-therapeutics-inc-prto-this-quarter.html.

Proteon Therapeutics (NASDAQ PRTO) traded up $0.05 during midday trading on Monday, reaching $1.85. The company had a trading volume of 32,600 shares, compared to its average volume of 114,606. Proteon Therapeutics has a 1-year low of $1.10 and a 1-year high of $11.45.

About Proteon Therapeutics

Proteon Therapeutics, Inc is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company’s product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access.

Get a free copy of the Zacks research report on Proteon Therapeutics (PRTO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Proteon Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteon Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply